Study on drug costs associated with COPD prescription medicine in Denmark

Clinical Respiratory Journal

Volumn 7, Issue 4, 2013, Pages 328-337

  Jakobsen, Marie ^a   Anker, Niels ^a   Dollerup, Jens ^b   Poulsen, Peter Bo ^b   Lange, Peter ^c  

^a COWI A/S ^*  (Denmark)

^b PFIZER INC   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

COPD; Costs; Denmark; Economics; Prescription drugs

Indexed keywords

BRONCHODILATING AGENT; FENOTEROL; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; PRESCRIPTION DRUG; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST OF ILLNESS; DENMARK; DRUG COST; FEE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

COPD; COSTS; DENMARK; ECONOMICS; PRESCRIPTION DRUGS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DENMARK; DRUG COSTS; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RETROSPECTIVE STUDIES; SPIROMETRY;

EID: 84884821170     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12010     Document Type: Article

References (24)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434): 613-620.
2. Lokke A, Fabricius PG, Vestbo J, Marott JL, Lange P. [Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from The Copenhagen City Heart Study]. Ugeskr Laeger. 2007;169(46): 3956-3960.
3. Ulrik CS, Lokke A, Dahl R, Dollerup J, Hansen G, Cording PH, Andersen KK. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis. 2011;6: 123-127.
4. Sundhedsstyrelsen. KOL - Kronisk Obstruktiv Lungesygdom. Anbefalinger for tidlig opsporing, opfølgning, behandling og rehabiltering. Sundhedsstyrelsen 2007. Available at: http://www.sst.dk/publ/Publ2007/CFF/KOL/KOLanbefalinger.pdf (accessed 16 April 2012).
5. Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med. 2011;17(Suppl. 1): S35-41.
6. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2011. Available at: http://www.goldcopd.org (accessed 12 March 2012).
7. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5: 341-349.
8. Chapman KR, Mannino DM, Soriano JB, etal. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1): 188-207.
9. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 years follow up study of the general population. Thorax. 2006;61(11): 935-939.
10. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandstrom T, Larsson K. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97(2): 115-122.
11. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339(17): 1194-1200.
12. Mannino DM, Martinez FJ. Lifetime risk of COPD: what will the future bring? Lancet. 2011;378(9795): 964-965.
13. Bilde L, Rud SA, Dollerup J, Baekke BH, Lange P. The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls. Respir Med. 2007;101(3): 539-546.
14. Danmarks Statistik. Håndbog til data i lægemiddeldatabasen. 2010. Available at: http://www.dst.dk/da/TilSalg/Forskningsservice/Data/~/media/5138925BB20B4DA8B728C4AFC6C837FE.pdf (accessed 8 April 2012).
15. Thomsen RW, Lange P, Hellquist B, Frausing E, Bartels PD, Krog R, Hansen AS, Buck D, Bunk AE. Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry. Respir Med. 2011;105(7): 1063-1068.
16. Triplett JE. Handbook on hedonic indexes and quality adjustments in price indexes: special application to information technology products. OECD Directorate for Science, Technology and Industry working paper October 2004. Available at: http://www.oecd.org/dataoecd/37/31/33789552.pdf (accessed 4 November 2012).
17. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med. 2003;97(Suppl. C): S3-14.
18. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis. 2008;3(1): 71-88.
19. Laegemiddelstyrelsen. Hvem bruger astmamedicin? Laegemiddelstyrelsen November 2011, Available at: http://www.laegemiddelstyrelsen.dk (accessed 13 March 2012).
20. Blanchette CM, Roberts MH, Petersen H, Dalal AA, Mapel DW. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis. 2011;6: 73-81.
21. Izquierdo-Alonso JL, de Miguel-Diez J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD. 2004;1(2): 215-223.
22. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AMB, Crapo RO, Jensen RL, Burney PGJ. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD. 2005;2(2): 277-283.
23. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B. Costs of COPD in Sweden according to disease severity. Chest. 2002;122(6): 1994-2002.
24. Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A, Sullivan SD, Lee TA. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J. 2009;34(4): 850-857.